OBJECTIVE -To evaluate the heterogeneity in the clinical expression in a family with glucokinase mature-onset diabetes of the young (GCK-MODY).
I
nactivating heterozygous mutations in the glucokinase gene (GCK) cause a form of monogenic diabetes with autosomal dominant inheritance (GCK mature-onset diabetes of the young [MODY]) (1, 2) . GCK-MODY has generally been considered a phenotypically homogenous mild form of diabetes, which does not lead to marked hyperglycemia or diabetes complications and does not need treatment (2) (3) (4) (5) .
Phenotypic heterogeneity within carriers of the same GCK mutation has been observed only in one family (6) . Here, we report a new GCK-MODY (GCK-G261R) family characterized by marked prandial hyperglycemia and unusual high levels of postprandial insulinemia.
RESEARCH DESIGN AND METHODS -The proband (online appendix Fig. A1 , available at http://care. diabetesjournals.org/cgi/content/full/ dc09-0681/DC1) was a firstborn child from a Finnish family with neonatal plasma glucose of 10 mmol/l. At 2 years of age, without treatment, she presented preprandial and postprandial capillary glucose of 6.5-6.8 and 8.6 mmol/l, respectively. Her younger sister had random glucose between 7 and 11.5 mmol/l as a neonate. Their mother was diagnosed with gestational diabetes and treated with insulin. After the pregnancy, she had an A1C of 5.8% without insulin treatment, but due to high postprandial plasma glucose (10 -11 mmol/l), rapid-acting mealtime insulin was started. Since the second pregnancy, she is treated with diet alone. The maternal grandmother presented with hyperglycemia and glucosuria at age of 22 years and gestational diabetes during four pregnancies. She was treated with diet during the first pregnancy and with insulin during three later pregnancies, after which she had been without treatment. Her fasting capillary glucose level was normally ϳ6 -7 mmol/l but stayed at ϳ10 mmol/l for nearly 2 weeks after intake of larger quantities of carbohydrates and returned to 6 -7 mmol/l when carbohydrates were restricted. She takes 60 mg of nateglinide before meals. All available family members were offered an oral glucose tolerance test (OGTT) and/or genetic testing for the mutation after genetic counseling.
OGTT (except subjects Ͻ15 years) with samples drawn at Ϫ5, 0, 30, 60, 90, and 120 min was performed to determine plasma glucose and serum insulin. Insulin resistance and ␤-cell function was estimated using the homeostasis model assessment of insulin resistance (HOMA IR ) and the insulinogenic indexes (IG30), respectively. The disposition index (DI) was used to assess ␤-cell compensation. These results and those from 15 subjects with GCK mutations in position 261 (GCK 261 ) from the European MODY Consortium Database (EMCD) (3) were compared with that of carriers of other missense and other types of GCK
mutations (insertions, deletions, etc.) (GCK m ) and normoglycemic control subjects from the Botnia Study (Table 1) . The studies were approved by the institutional ethics committee. Written consent was obtained from the adults and from the parents of the children. DNA extraction, microsatellite genotyping, direct sequencing, and functional analysis of the glucokinase protein (gk), with and without gk activator, were performed as described (7-10).
RESULTS -The mutation G261R (exon 7) on GCK was found in the proband and in nine family members (aged 0.2-72 years) with abnormal fasting glucose. Fasting plasma glucose ranged from 6.0 to 7.6 mmol/l. The 2-h plasma glucose ranged from 9.3 to 14.5 mmol/l in the carriers, three of them presented values exceeding 13 mmol/l. All but one of the carriers had a 2-h increment in plasma glucose (2h⌬PG) higher than 3 mmol/l and half higher than 6 mmol/l. Fasting insulin was 4.1-9.9 mU/l and 2-h insulin 28.8 -61.9 mU/l. There was no relationship between age and glucose or insulin concentrations.
The GCK 261 mutation carriers from our family, like those from the EMCD, had a significantly higher glucose and insulin response compared with GCK m carriers (Table 1) . Fasting plasma glucose and insulin were similar in all groups; however, the 2-h plasma glucose and insulin and 2h⌬PG values were significantly higher in GCK 261 carriers than in GCK m carriers ( Table 1 ). The glucose response during OGTT was higher at all time points in GCK 261 carriers compared also with GCK m carriers (data not shown). In 61 and 35% of GCK 261 carriers, 2h⌬PG was Ͼ3 and 4.6 mmol/l, respectively. HOMA IR , I/G30, and DI values were higher (not significant) in the GCK 261 carriers (Table 1) , indicating possibly higher degree of ␤-cell compensation ( Table 1) .
The results from the functional studies showed that the mutations gk-G261R/E lead to a severely effected protein, with an almost negligible enzyme activity, indicating that these gk mutants cannot contribute to ␤-cell and hepatic glucose phosphorylation. The effect of the gk activator on the inactivating gk-G261R mutation was similar to that on the gk-WT (see online appendix Table A1 ).
CONCLUSIONS -The clinical phenotype of carriers from our family was heterogeneous. The proband and her sister presented with neonatal hyperglycemia, their mother with gestational diabetes, and the maternal grandmother with glucosuria. Many carriers had much higher 2h⌬PG values than what is usually seen in GCK-MODY. In three carriers (one child and two adults), it exceeded 13 mmol/l and in another young carrier 12 mmol/l, indicating no relationship between high 2h⌬PG values and age. A sim- data are means of the three independent analyses. Results of the functional studies of gk-WT and mutants gk-G261R and gk-G261E. AI, the activity index for the enzyme was calculated as previously described (8) . Glucose S 0.5 of gk-G261R mutations was carried out with 25 mmol/l of MgATP, and the ATP Km measurement was performed at glucose concentration of 500 mmol/l. T-GSIR, threshold for glucose-stimulated insulin secretion.
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care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010ilar pattern was seen in other carriers of the same mutation, while those with other GCK mutations in the MODY database had a lower glucose response during OGTT. Of note, a similar pattern of glucose response as in GCK 261 carriers has previously been observed in GCK-L184P carriers (6) . However, while the insulin response was attenuated in GCK-L184P carriers, in GCK 261 carriers it was high and significantly different from that seen with other GCK mutations (11). Glucokinase is required for glycogen synthesis in liver (12) . One explanation for the high 2-h glucose in GCK 261 carriers could be reduced hepatic glycogen synthesis due to the lost of activity of GCK 261 . Hence, the marked insulin response could be due to larger ␤-cell compensation in GCK 261 carriers. Nonetheless, possible additional genetic defects could be also involved. In summary, the clinical phenotype of patients with GCK-MODY can be heterogeneous and patients carrying severe inactivating GCK mutations can have high postchallenge glucose values, possibly resulting from a marked liver component of the disease.
